13 November 2010 - NICE CG53 REVIEW - STAKEHOLDER COMMENTS:

NICE is undertaking its scheduled 3-yearly review of its 'CFS/ME' Clinical Guideline 53 during a very short-lived consultation period of 1st to 14th November 2010. The executive view NICE has already declared for its review however is that it sees no reason not to leave CG53 unchanged: by claiming there is no new evidence that warrants rewriting of their original Guideline published in August 2007. See the NICE web addresses below for further details.

The text of the two respective Stakeholder Responses from the 25% ME Group and the East Anglia ME Patient Partnership (EAME) are now available online at:

http://www.angliameaction.org.uk/docs/25megroup-nice-cg53-response-nov2010.pdf

http://www.angliameaction.org.uk/docs/eame-nice-cg53-response-nov2010.pdf

I believe these stakeholder responses utterly demolish any claim NICE has that the core CBT/GET treatments they recommended are genuinely evidence-based. They similarly remove any doubt that it is just patients that believe CG53 is "unfit for purpose" and call for an urgent rewriting of CG53 by a completely different Guideline Development Group.

NICE CG53 Review Addresses:

http://www.nice.org.uk/guidance/index.jsp?action=folder&o=51432
http://www.nice.org.uk/_gs/link/?id=F881B2AB-19B9-E0B5-D4CFD07D161064A9
http://www.nice.org.uk/nicemedia/live/11824/51425/51425.pdf